Seattle police chief resigns under pressure from mayor over response to festival shootingJuly 30, 2026
J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell TherapyNews DeskJuly 30, 20260 Johnson & Johnson, which was part of the wave of the first cell therapies, is now getting a next-generation contender…
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent DisordersNews DeskJuly 27, 20260 Argenx established itself in immunology with a single drug offering potential use across a range of rare inflammatory disorders. The…
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout DrugNews DeskJuly 26, 20260 Crystalys Therapeutics does not yet have data from pivotal tests of its gout drug, but the company is already looking…
After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen AssetNews DeskJuly 14, 20260 Spero Therapeutics, a company whose history in antibiotics research culminated in the recent FDA nod for its first product, is…